<?xml version="1.0" encoding="utf-8"?>
<rss 
  version="2.0">
  <channel xmlns:dc="http://dublincore.org/documents/dcmi-namespace/" xmlns:media="http://search.yahoo.com/mrss/">
    <title>VBI Vaccines Inc.</title>
    <link>https://www.globenewswire.com/rssfeed/organization/kAaQvZBpM5xDRxPQo9WI7g==</link>
    <description>Contains the last 20 releases</description>
    <copyright>Copyright 2017, VBI Vaccines Inc.</copyright>
    <managingEditor>newsdesk@globenewswire.com (NewsDesk)</managingEditor>
    <lastBuildDate>Tue, 17 Oct 2017 12:00:00 GMT</lastBuildDate>
    <webMaster>webmaster@globenewswire.com (Webmaster)</webMaster>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2017/10/17/1152998/0/en/VBI-Vaccines-Hepatitis-B-Data-Selected-as-Presidential-Poster-of-Distinction-at-The-Liver-Meeting-R-2017.html</guid>
      <link>https://www.globenewswire.com/news-release/2017/10/17/1152998/0/en/VBI-Vaccines-Hepatitis-B-Data-Selected-as-Presidential-Poster-of-Distinction-at-The-Liver-Meeting-R-2017.html</link>
      <title>VBI Vaccines Hepatitis B Data Selected as Presidential Poster of Distinction at The Liver Meeting(R) 2017</title>
      <description><![CDATA[<p><em><p>- Poster presentation to feature data from VBI's Phase IV clinical study of Sci-B-Vac(R), which demonstrated rapid seroprotection and high levels of hepatitis B antibodies after two vaccinations</p><p></p><p>- Sci-B-Vac(R) is a third-generation Hepatitis B vaccine that contains the S antigen, pre-S1, and pre-S2 surface antigens of the Hepatitis B virus</p></em></p><p><strong>CAMBRIDGE, MASSACHUSETTS--(Marketwired - Oct. 17, 2017) -</strong> VBI Vaccines Inc. (NASDAQ:VBIV)(TSX:VBV) (VBI) today announced the company's abstract, "Antibody and Cell-mediated Immunity against PreS1, PreS2, and S Antigens after Immunizations with a Third Generation Hepatitis B Vaccine," has been selected as a Presidential Poster of Distinction for presentation at the 68<sup>th</sup> annual meeting of the American Association for the Study of Liver Diseases (AASLD), The Liver Meeting&#174; 2017, in Washington D.C. on October 23, 2017. </p>]]></description>
      <pubDate>Tue, 17 Oct 2017 12:00 GMT</pubDate>
      <dc:identifier>1152998</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>VBI Vaccines Inc.</dc:contributor>
      <dc:modified>Wed, 25 Oct 2017 06:16 GMT</dc:modified>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2017/10/11/1152997/0/en/VBI-Vaccines-to-Present-at-The-World-Vaccine-Congress-Europe-2017-in-Barcelona.html</guid>
      <link>https://www.globenewswire.com/news-release/2017/10/11/1152997/0/en/VBI-Vaccines-to-Present-at-The-World-Vaccine-Congress-Europe-2017-in-Barcelona.html</link>
      <title>VBI Vaccines to Present at The World Vaccine Congress Europe 2017 in Barcelona</title>
      <description><![CDATA[<p><em><p>Presentation to feature overview of positive interim Phase 1 CMV vaccine data and preclinical Zika vaccine data demonstrating neutralizing antibody response</p></em></p><p><strong>CAMBRIDGE, MASSACHUSETTS--(Marketwired - Oct. 11, 2017) -</strong> VBI Vaccines Inc. (NASDAQ:VBIV)(TSX:VBV) (VBI) today announced that Adam Buckley, vice president of business development, will discuss VBI's enveloped virus-like particle (eVLP) platform, highlighting data from two of the company's vaccine programs, during a presentation at the World Vaccine Congress Europe held Oct. 10-12, 2017, in Barcelona.</p>]]></description>
      <pubDate>Wed, 11 Oct 2017 12:00 GMT</pubDate>
      <dc:identifier>1152997</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>VBI Vaccines Inc.</dc:contributor>
      <dc:modified>Wed, 25 Oct 2017 06:16 GMT</dc:modified>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2017/09/12/1152994/0/en/VBI-Vaccines-to-Present-at-September-2017-Investor-Conferences.html</guid>
      <link>https://www.globenewswire.com/news-release/2017/09/12/1152994/0/en/VBI-Vaccines-to-Present-at-September-2017-Investor-Conferences.html</link>
      <title>VBI Vaccines to Present at September 2017 Investor Conferences</title>
      <description><![CDATA[<p><strong>CAMBRIDGE, MASSACHUSETTS--(Marketwired - Sept. 12, 2017) -</strong> VBI Vaccines Inc. (NASDAQ:VBIV)(TSX:VBV) (VBI) today announced that Jeff Baxter, President and CEO, will provide a corporate overview and update at two investor conferences in September. </p>]]></description>
      <pubDate>Tue, 12 Sep 2017 12:00 GMT</pubDate>
      <dc:identifier>1152994</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>VBI Vaccines Inc.</dc:contributor>
      <dc:modified>Wed, 25 Oct 2017 06:16 GMT</dc:modified>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2017/08/30/1152993/0/en/VBI-Vaccines-Announces-FDA-Acceptance-of-Investigational-New-Drug-Application-for-Sci-B-Vac-R-Phase-3-Clinical-Program.html</guid>
      <link>https://www.globenewswire.com/news-release/2017/08/30/1152993/0/en/VBI-Vaccines-Announces-FDA-Acceptance-of-Investigational-New-Drug-Application-for-Sci-B-Vac-R-Phase-3-Clinical-Program.html</link>
      <title>VBI Vaccines Announces FDA Acceptance of Investigational New Drug Application for Sci-B-Vac(R) Phase 3 Clinical Program</title>
      <description><![CDATA[<p><strong>CAMBRIDGE, MASSACHUSETTS--(Marketwired - Aug. 30, 2017) -</strong> </p>]]></description>
      <pubDate>Wed, 30 Aug 2017 12:00 GMT</pubDate>
      <dc:identifier>1152993</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>VBI Vaccines Inc.</dc:contributor>
      <dc:modified>Wed, 25 Oct 2017 06:16 GMT</dc:modified>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2017/08/28/1152991/0/en/VBI-Vaccines-to-Present-New-Preclinical-Data-for-its-GBM-Immunotherapy-VBI-1901-at-The-Immuno-Oncology-Summit.html</guid>
      <link>https://www.globenewswire.com/news-release/2017/08/28/1152991/0/en/VBI-Vaccines-to-Present-New-Preclinical-Data-for-its-GBM-Immunotherapy-VBI-1901-at-The-Immuno-Oncology-Summit.html</link>
      <title>VBI Vaccines to Present New Preclinical Data for its GBM Immunotherapy, VBI-1901, at The Immuno-Oncology Summit</title>
      <description><![CDATA[<p><em><p>- IND-enabling data, including restimulation of CMV-specific T-cell immunity in Rhesus Macaques</p><p></p><p>- Mechanistic data demonstrating VBI-1901 stimulates innate immunity </p><p></p><p>- Data presentation Wednesday, Aug. 30</p></em></p><p><strong>CAMBRIDGE, MASSACHUSETTS--(Marketwired - Aug. 28, 2017) -</strong> VBI Vaccines Inc. (NASDAQ:VBIV)(TSX:VBV) (VBI) today announced that David Anderson, Ph.D., Chief Scientific Officer of VBI, will present new preclinical data demonstrating the mechanism by which VBI-1901 stimulates CMV-specific immunity in monkeys at The Immuno-Oncology Summit in Boston on Wednesday, Aug. 30, 2017. VBI-1901 is a novel immunotherapy developed using VBI's eVLP technology to target CMV-positive (CMV+) tumors, including glioblastoma multiforme (GBM), the company's lead immuno-oncology program. </p>]]></description>
      <pubDate>Mon, 28 Aug 2017 12:30 GMT</pubDate>
      <dc:identifier>1152991</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>VBI Vaccines Inc.</dc:contributor>
      <dc:modified>Wed, 25 Oct 2017 06:16 GMT</dc:modified>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2017/08/15/1152989/0/en/VBI-Vaccines-Announces-FDA-Acceptance-of-Investigational-New-Drug-Application-for-VBI-1901-to-Treat-Glioblastoma-Multiforme.html</guid>
      <link>https://www.globenewswire.com/news-release/2017/08/15/1152989/0/en/VBI-Vaccines-Announces-FDA-Acceptance-of-Investigational-New-Drug-Application-for-VBI-1901-to-Treat-Glioblastoma-Multiforme.html</link>
      <title>VBI Vaccines Announces FDA Acceptance of Investigational New Drug Application for VBI-1901 to Treat Glioblastoma Multiforme</title>
      <description><![CDATA[<p><em><p>VBI-1901 is a novel immunotherapy developed using VBI's eVLP technology</p><p></p><p>On track to initiate a Phase I/2a clinical study in the second half of 2017</p></em></p><p><strong>CAMBRIDGE, MASSACHUSETTS--(Marketwired - Aug. 15, 2017) -</strong> VBI Vaccines Inc. (NASDAQ:VBIV) (TSX:VBV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's Investigational New Drug Application (IND) for VBI-1901, a novel immunotherapy targeting Glioblastoma Multiforme (GBM), one of the most common and aggressive malignant primary brain tumors in humans. The IND enables VBI to initiate a multi-center Phase I/2a clinical study evaluating VBI-1901 in patients with recurrent GBM in the second half of this year. </p>]]></description>
      <pubDate>Tue, 15 Aug 2017 12:30 GMT</pubDate>
      <dc:identifier>1152989</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>VBI Vaccines Inc.</dc:contributor>
      <dc:modified>Wed, 25 Oct 2017 06:16 GMT</dc:modified>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2017/07/27/1152987/0/en/VBI-Vaccines-Announces-Positive-Interim-Data-from-Phase-1-Study-of-Preventative-CMV-Vaccine.html</guid>
      <link>https://www.globenewswire.com/news-release/2017/07/27/1152987/0/en/VBI-Vaccines-Announces-Positive-Interim-Data-from-Phase-1-Study-of-Preventative-CMV-Vaccine.html</link>
      <title>VBI Vaccines Announces Positive Interim Data from Phase 1 Study of Preventative CMV Vaccine</title>
      <description><![CDATA[<p><em><p>Well tolerated at all doses with no safety signals</p><p></p><p>100% seroconversion at highest dose after two of the three planned vaccinations</p><p></p><p>Dose-dependent antibody responses against CMV gB antigen</p><p></p><p>Full data after third dose expected first half of 2018</p><p></p><p>Conference Call and Webcast: Thursday, July 27, 2017, at 1:00 p.m. EDT</p></em></p><p><strong>CAMBRIDGE, MASSACHUSETTS--(Marketwired - July 27, 2017) -</strong> VBI Vaccines Inc. (NASDAQ:VBIV)(TSX:VBV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced positive results from a planned, interim data read-out from a Phase 1 study of its preventative cytomegalovirus (CMV) vaccine.</p>]]></description>
      <pubDate>Thu, 27 Jul 2017 11:30 GMT</pubDate>
      <dc:identifier>1152987</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>VBI Vaccines Inc.</dc:contributor>
      <dc:modified>Wed, 25 Oct 2017 06:16 GMT</dc:modified>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2017/07/11/1152985/0/en/VBI-Vaccines-Announces-Phase-3-Clinical-Program-for-Sci-B-Vac-TM-Hepatitis-B-Vaccine.html</guid>
      <link>https://www.globenewswire.com/news-release/2017/07/11/1152985/0/en/VBI-Vaccines-Announces-Phase-3-Clinical-Program-for-Sci-B-Vac-TM-Hepatitis-B-Vaccine.html</link>
      <title>VBI Vaccines Announces Phase 3 Clinical Program for Sci-B-Vac(TM) Hepatitis B Vaccine</title>
      <description><![CDATA[<p><em><p>Conference Call and Webcast: Wednesday, July 12, at 8:30 a.m. EDT</p></em></p><p><strong>CAMBRIDGE, MASSACHUSETTS--(Marketwired - July 11, 2017) -</strong> VBI Vaccines Inc. (NASDAQ:VBIV)(TSX:VBV) ("VBI") announced today its plans for a global Phase 3 clinical program for Sci-B-Vac&#8482;, its third-generation hepatitis B vaccine, following positive discussions with the U.S. Food &amp; Drug Administration (FDA), the European Medicines Agency (EMA), and Health Canada. </p>]]></description>
      <pubDate>Tue, 11 Jul 2017 20:05 GMT</pubDate>
      <dc:identifier>1152985</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>VBI Vaccines Inc.</dc:contributor>
      <dc:modified>Wed, 25 Oct 2017 06:16 GMT</dc:modified>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2017/06/28/1152982/0/en/VBI-Vaccines-Announces-Results-of-Annual-General-and-Special-Meeting.html</guid>
      <link>https://www.globenewswire.com/news-release/2017/06/28/1152982/0/en/VBI-Vaccines-Announces-Results-of-Annual-General-and-Special-Meeting.html</link>
      <title>VBI Vaccines Announces Results of Annual General and Special Meeting</title>
      <description><![CDATA[<p><strong>CAMBRIDGE, MASSACHUSETTS--(Marketwired - June 28, 2017) -</strong> VBI Vaccines Inc. (NASDAQ:VBIV)(TSX:VBV) ("VBI") today announced the voting results from its annual general and special meeting (the "<strong>Meeting</strong>") held on June 22, 2017.</p>]]></description>
      <pubDate>Wed, 28 Jun 2017 21:00 GMT</pubDate>
      <dc:identifier>1152982</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>VBI Vaccines Inc.</dc:contributor>
      <dc:modified>Wed, 25 Oct 2017 06:15 GMT</dc:modified>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2017/06/26/1152980/0/en/VBI-Vaccines-Added-to-Russell-2000-and-Russell-3000-Indexes.html</guid>
      <link>https://www.globenewswire.com/news-release/2017/06/26/1152980/0/en/VBI-Vaccines-Added-to-Russell-2000-and-Russell-3000-Indexes.html</link>
      <title>VBI Vaccines Added to Russell 2000® and Russell 3000® Indexes</title>
      <description><![CDATA[<p><strong>CAMBRIDGE, MASSACHUSETTS--(Marketwired - June 26, 2017) -</strong> VBI Vaccines, Inc. (NASDAQ:VBIV)(TSX:VBV) ("VBI"), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, announced today that it has been added to the Russell 2000<sup>&#174;</sup> and the Russell 3000<sup>&#174;</sup> Indexes following the annual reconstitution, which took effect after the US market closed on Friday, June 23rd. </p>]]></description>
      <pubDate>Mon, 26 Jun 2017 12:30 GMT</pubDate>
      <dc:identifier>1152980</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>VBI Vaccines Inc.</dc:contributor>
      <dc:modified>Wed, 25 Oct 2017 06:15 GMT</dc:modified>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2017/06/19/1152979/0/en/VBI-Vaccines-Reports-Positive-Outcome-from-Phase-III-Pre-IND-Discussions-with-the-FDA-for-Hepatitis-B-Vaccine-Sci-B-Vac-TM.html</guid>
      <link>https://www.globenewswire.com/news-release/2017/06/19/1152979/0/en/VBI-Vaccines-Reports-Positive-Outcome-from-Phase-III-Pre-IND-Discussions-with-the-FDA-for-Hepatitis-B-Vaccine-Sci-B-Vac-TM.html</link>
      <title>VBI Vaccines Reports Positive Outcome from Phase III Pre-IND Discussions with the FDA for Hepatitis B Vaccine, Sci-B-Vac(TM)</title>
      <description><![CDATA[<p><strong>CAMBRIDGE, MASSACHUSETTS--(Marketwired - June 19, 2017) -</strong> VBI Vaccines Inc. (NASDAQ:VBIV)(TSX:VBV) ("VBI"), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, announced today that it has completed a pre-Investigational New Drug ("IND") meeting with the U.S. Food and Drug Administration ("FDA") to discuss the Phase III clinical program for <a rel="nofollow" href="https://www.vbivaccines.com/sci-b-vac/" title="Sci-B-Vac&#8482;">Sci-B-Vac&#8482;</a>, VBI's third-generation hepatitis B vaccine. Sci-B-Vac&#8482; is currently approved for use in Israel and 14 other countries worldwide. </p>]]></description>
      <pubDate>Mon, 19 Jun 2017 12:30 GMT</pubDate>
      <dc:identifier>1152979</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>VBI Vaccines Inc.</dc:contributor>
      <dc:modified>Wed, 25 Oct 2017 06:15 GMT</dc:modified>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2017/06/05/1152975/0/en/VBI-Vaccines-to-Present-at-Jefferies-2017-Global-Healthcare-Conference.html</guid>
      <link>https://www.globenewswire.com/news-release/2017/06/05/1152975/0/en/VBI-Vaccines-to-Present-at-Jefferies-2017-Global-Healthcare-Conference.html</link>
      <title>VBI Vaccines to Present at Jefferies 2017 Global Healthcare Conference</title>
      <description><![CDATA[<p><strong>CAMBRIDGE, MASSACHUSETTS--(Marketwired - June 5, 2017) -</strong> VBI Vaccines Inc. (NASDAQ:VBIV)(TSX:VBV) ("VBI"), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that Jeff Baxter, VBI's President and CEO, will present at the Jefferies 2017 Global Healthcare Conference on Friday, June 9, 2017 at 12:30 PM ET in New York City. </p>]]></description>
      <pubDate>Mon, 05 Jun 2017 12:30 GMT</pubDate>
      <dc:identifier>1152975</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>VBI Vaccines Inc.</dc:contributor>
      <dc:modified>Wed, 25 Oct 2017 06:15 GMT</dc:modified>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2017/05/02/1152970/0/en/VBI-Vaccines-Provides-Update-on-its-Congenital-CMV-Phase-I-Clinical-Study.html</guid>
      <link>https://www.globenewswire.com/news-release/2017/05/02/1152970/0/en/VBI-Vaccines-Provides-Update-on-its-Congenital-CMV-Phase-I-Clinical-Study.html</link>
      <title>VBI Vaccines Provides Update on its Congenital CMV Phase I Clinical Study</title>
      <description><![CDATA[<p><em><p>Positive Safety Review and Final Vaccination of All Participants</p></em></p><p><strong>CAMBRIDGE, MASSACHUSETTS--(Marketwired - May 2, 2017) -</strong> VBI Vaccines Inc. (NASDAQ:VBIV) (TSX:VBV) ("VBI") today provided an update on its cytomegalovirus ("CMV") Phase I clinical study, which is assessing the safety and tolerability of VBI's <a rel="nofollow" href="https://www.vbivaccines.com/cmv/" title="vaccine candidate to prevent congenital CMV infection">vaccine candidate to prevent congenital CMV infection</a>. Congenital CMV infection is a leading cause of birth defects, affecting more live births than Down syndrome or fetal alcohol syndrome, making it a key public health priority. </p>]]></description>
      <pubDate>Tue, 02 May 2017 12:30 GMT</pubDate>
      <dc:identifier>1152970</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>VBI Vaccines Inc.</dc:contributor>
      <dc:modified>Wed, 25 Oct 2017 06:15 GMT</dc:modified>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2017/04/05/1152967/0/en/VBI-Vaccines-to-Present-Updates-on-Multiple-Programs-at-the-World-Vaccine-Congress.html</guid>
      <link>https://www.globenewswire.com/news-release/2017/04/05/1152967/0/en/VBI-Vaccines-to-Present-Updates-on-Multiple-Programs-at-the-World-Vaccine-Congress.html</link>
      <title>VBI Vaccines to Present Updates on Multiple Programs at the World Vaccine Congress</title>
      <description><![CDATA[<p><strong>CAMBRIDGE, MASSACHUSETTS--(Marketwired - April 5, 2017) -</strong> VBI Vaccines Inc. (NASDAQ:VBIV)(TSX:VBV) ("VBI") is scheduled to present updates on two of its programs at the <a rel="nofollow" href="http://www.terrapinn.com/conference/world-vaccine-congress-washington/index.stm" title="World Vaccine Congress">World Vaccine Congress</a> on Tuesday, April 11, 2017 at 3:40 PM ET and 4:40 PM ET. The event is being held at the Grand Hyatt in Washington, D.C.</p>]]></description>
      <pubDate>Wed, 05 Apr 2017 12:30 GMT</pubDate>
      <dc:identifier>1152967</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>VBI Vaccines Inc.</dc:contributor>
      <dc:modified>Wed, 25 Oct 2017 06:15 GMT</dc:modified>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2017/03/30/1152964/0/en/VBI-Vaccines-Appoints-Avi-Mazaltov-as-Global-Head-of-Manufacturing-and-SciVac-General-Manager-Rehovot-Israel-Site.html</guid>
      <link>https://www.globenewswire.com/news-release/2017/03/30/1152964/0/en/VBI-Vaccines-Appoints-Avi-Mazaltov-as-Global-Head-of-Manufacturing-and-SciVac-General-Manager-Rehovot-Israel-Site.html</link>
      <title>VBI Vaccines Appoints Avi Mazaltov as Global Head of Manufacturing and SciVac General Manager; Rehovot, Israel Site</title>
      <description><![CDATA[<p><strong>CAMBRIDGE, MASSACHUSETTS--(Marketwired - March 30, 2017) -</strong> VBI Vaccines Inc. (NASDAQ:VBIV)(TSX:VBV) ("VBI") and <a rel="nofollow" href="https://www.vbivaccines.com/scivac/" title="SciVac Ltd.">SciVac Ltd.</a> ("SciVac"), a wholly owned subsidiary of VBI, are pleased to announce the appointment of Avi Mazaltov as the Global Head of Manufacturing and General Manager of the SciVac manufacturing site in Rehovot, Israel. </p>]]></description>
      <pubDate>Thu, 30 Mar 2017 12:30 GMT</pubDate>
      <dc:identifier>1152964</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>VBI Vaccines Inc.</dc:contributor>
      <dc:modified>Wed, 25 Oct 2017 06:15 GMT</dc:modified>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2017/02/22/1152962/0/en/VBI-Vaccines-Receives-Positive-Response-from-Health-Canada-s-Initial-Evaluation-of-the-Proposed-Sci-B-Vac-Phase-III-Clinical-Program.html</guid>
      <link>https://www.globenewswire.com/news-release/2017/02/22/1152962/0/en/VBI-Vaccines-Receives-Positive-Response-from-Health-Canada-s-Initial-Evaluation-of-the-Proposed-Sci-B-Vac-Phase-III-Clinical-Program.html</link>
      <title>VBI Vaccines Receives Positive Response from Health Canada's Initial Evaluation of the Proposed Sci-B-Vac Phase III Clinical Program</title>
      <description><![CDATA[<p><strong>CAMBRIDGE, MASSACHUSETTS--(Marketwired - Feb. 22, 2017) -</strong> VBI Vaccines Inc. (NASDAQ:VBIV)(TSX:VBV) ("VBI") announced today that the Biologics and Genetic Therapies Directorate (BGTD) of Health Canada expressed its general support and acceptance of the company's development path for its <a rel="nofollow" href="https://www.vbivaccines.com/sci-b-vac/" title="Sci-B-Vac">Sci-B-Vac</a>&#8482; vaccine, a prophylactic vaccine against hepatitis B, in a pre-Clinical Trial Application ("CTA") meeting. A complete CTA must be filed with and approved by BGTD, and all conditions of BGTD must be met, prior to the initiation of a clinical program in Canada.</p>]]></description>
      <pubDate>Wed, 22 Feb 2017 13:30 GMT</pubDate>
      <dc:identifier>1152962</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>VBI Vaccines Inc.</dc:contributor>
      <dc:modified>Wed, 25 Oct 2017 06:15 GMT</dc:modified>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2017/02/07/1152960/0/en/VBI-Vaccines-Receives-Positive-EMA-Scientific-Advice-Regarding-Sci-B-Vac-TM-Phase-III-Clinical-Study.html</guid>
      <link>https://www.globenewswire.com/news-release/2017/02/07/1152960/0/en/VBI-Vaccines-Receives-Positive-EMA-Scientific-Advice-Regarding-Sci-B-Vac-TM-Phase-III-Clinical-Study.html</link>
      <title>VBI Vaccines Receives Positive EMA Scientific Advice Regarding Sci-B-Vac(TM)  Phase III Clinical Study</title>
      <description><![CDATA[<p><strong>CAMBRIDGE, MASSACHUSETTS--(Marketwired - Feb. 7, 2017) -</strong> VBI Vaccines Inc. (NASDAQ:VBIV) (TSX:VBV) ("VBI") announced today the receipt of positive Scientific Advice from the Committee for Medicinal Products for Human Use (CHMP) of the European Medical Agency (EMA) regarding the company's development path for its Sci-B-Vac&#8482; vaccine in Europe. Sci-B-Vac&#8482; is a third-generation hepatitis B vaccine with demonstrated safety and efficacy in over 300,000 patients in currently licensed markets.</p>]]></description>
      <pubDate>Tue, 07 Feb 2017 13:30 GMT</pubDate>
      <dc:identifier>1152960</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>VBI Vaccines Inc.</dc:contributor>
      <dc:modified>Wed, 25 Oct 2017 06:15 GMT</dc:modified>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2016/12/06/1152959/0/en/VBI-Vaccines-Closes-23-6-Million-Financing-from-Perceptive-Advisors.html</guid>
      <link>https://www.globenewswire.com/news-release/2016/12/06/1152959/0/en/VBI-Vaccines-Closes-23-6-Million-Financing-from-Perceptive-Advisors.html</link>
      <title>VBI Vaccines Closes $23.6 Million Financing from Perceptive Advisors</title>
      <description><![CDATA[<p><strong>CAMBRIDGE, MASSACHUSETTS--(Marketwired - Dec. 6, 2016) -</strong> VBI Vaccines Inc. (NASDAQ:VBIV) (TSX:VBV) ("VBI"), a clinical-stage biopharmaceutical company developing infectious disease and immuno-oncology vaccines, today announced that it has raised $23.6 million in concurrent equity and debt financing transactions with Perceptive Advisors. </p>]]></description>
      <pubDate>Tue, 06 Dec 2016 13:30 GMT</pubDate>
      <dc:identifier>1152959</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>VBI Vaccines Inc.</dc:contributor>
      <dc:modified>Wed, 25 Oct 2017 06:15 GMT</dc:modified>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2016/11/14/1152956/0/en/VBI-Vaccines-Reports-Rapid-Seroprotection-Results-from-an-Interim-Analysis-of-a-Phase-IV-Postmarketing-Study-of-its-Sci-B-Vac-TM-Hepatitis-B-Vaccine.html</guid>
      <link>https://www.globenewswire.com/news-release/2016/11/14/1152956/0/en/VBI-Vaccines-Reports-Rapid-Seroprotection-Results-from-an-Interim-Analysis-of-a-Phase-IV-Postmarketing-Study-of-its-Sci-B-Vac-TM-Hepatitis-B-Vaccine.html</link>
      <title>VBI Vaccines Reports Rapid Seroprotection Results from an Interim Analysis of a Phase IV Postmarketing Study of its Sci-B-Vac(TM) Hepatitis B Vaccine</title>
      <description><![CDATA[<p><em><p>98.8% of Patients Seroprotected at Two Months Following Second Dose of Sci-B-Vac(TM)</p></em></p><p><strong>CAMBRIDGE, MASSACHUSETTS--(Marketwired - Nov. 14, 2016) -</strong> VBI Vaccines Inc. (NASDAQ:VBIV)(TSX:VBV) ("VBI") today reported interim results from an ongoing Phase IV postmarketing study to evaluate <a rel="nofollow" href="https://www.vbivaccines.com/sci-b-vac/" title="Sci-B-Vac&#8482;">Sci-B-Vac&#8482;</a>, VBI's licensed third-generation hepatitis B vaccine, in healthy adults. </p>]]></description>
      <pubDate>Mon, 14 Nov 2016 13:30 GMT</pubDate>
      <dc:identifier>1152956</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>VBI Vaccines Inc.</dc:contributor>
      <dc:modified>Wed, 25 Oct 2017 06:15 GMT</dc:modified>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2016/11/10/1152954/0/en/VBI-Vaccines-to-Present-at-the-Society-of-Neuro-Oncology-Annual-Meeting.html</guid>
      <link>https://www.globenewswire.com/news-release/2016/11/10/1152954/0/en/VBI-Vaccines-to-Present-at-the-Society-of-Neuro-Oncology-Annual-Meeting.html</link>
      <title>VBI Vaccines to Present at the Society of Neuro-Oncology Annual Meeting</title>
      <description><![CDATA[<p><strong>CAMBRIDGE, MASSACHUSETTS--(Marketwired - Nov. 10, 2016) -</strong> VBI Vaccines Inc. (NASDAQ:VBIV)(TSX:VBV) ("VBI") is scheduled to present at the Society of Neuro-Oncology Annual Meeting on Friday, November 18, 2016 at 7:00 PM MST (5:00 PM EST). The event is being held at the Scottsdale Fairmont Princess Hotel in Scottsdale, AZ.</p>]]></description>
      <pubDate>Thu, 10 Nov 2016 13:30 GMT</pubDate>
      <dc:identifier>1152954</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>VBI Vaccines Inc.</dc:contributor>
      <dc:modified>Wed, 25 Oct 2017 06:15 GMT</dc:modified>
    </item>
  </channel>
</rss>